Clinical Trials
4 trialsNCT03539536 2025-11-05
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
AbbVie
Phase 2 Active not recruiting
NCT03248492 2025-06-26
DESTINY-Breast01
Daiichi Sankyo
Phase 2 Terminated
NCT03505710 2025-05-30
DESTINY-Lung01
Daiichi Sankyo
Phase 2 Terminated
NCT02414139 2024-03-20
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Novartis
Phase 2 Completed